Alnylam Pharmaceuticals experienced significant changes with its stock rallying
3.8% in one week and a remarkable
246% gain over five years. The shares significantly surged after the biotech reported
positive outcomes of the drug trial for a
rare heart disease. The company also announced its CEO
Yvonne Greenstreet sold over $1.85 million of her shares of the company stock. Alnylam along with Medison Pharma expanded their
partnership to commercialize RNAi therapeutics in more markets. Alnylam announced
positive results for its heart drug in a pivotal study, increasing the likely path to
approval. Conversely, changes to the heart drug trial raised doubts leading to a downfall in shares, although they later surged with positive trial results being announced. Recently, Greenstreet was named 2024 Woman of the Year by the Healthcare Businesswomen’s Association and there are rumors of more innovation
within the firm.
Alnylam Pharmaceuticals News Analytics from Wed, 13 Sep 2023 07:00:00 GMT to Sun, 14 Jul 2024 18:43:57 GMT -
Rating 8
- Innovation 6
- Information 8
- Rumor -4
